Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 19/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2518892 | 0.93 | CCR5 (0.61) | CCR5 | |
| SCHEMBL16503435 | 0.86 | CCR5 (0.56) | CCR5 | |
| SCHEMBL4775197 | 0.86 | NPSR1 (0.56) | CCR5 | |
| SCHEMBL4768738 | 0.85 | POLB (0.56) | CCR5MEN1KMT2A | |
| SCHEMBL4775504 | 0.85 | CCR5 (0.73) | CCR5 | |
| SCHEMBL4776500 | 0.85 | CCR5 (0.70) | CCR5 | |
| SCHEMBL4773903 | 0.84 | CCR5 (0.67) | CCR5 | |
| SCHEMBL4774079 | 0.83 | CCR5 (0.75) | CCR5 | |
| SCHEMBL12207023 | 0.82 | CCR5 (0.86) | CCR5 | |
| SCHEMBL4773828 | 0.81 | CCR5 (0.66) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110313144-A1 | iRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| US-8034921-B2 | Chemokine receptors (CCR5); double stranded RNA; gene knockout | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20080255345-A1 | IRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-7348324-B2 | Cyclic amine compounds as CCR5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1886994-A1 | Cyclic amine compounds as CCR5 antagonists | Takeda Pharmaceutical Company Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-7049441-B2 | Process for preparation of benzylpiperidine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-23 | — | — | US | disclosed |
| US-20060094877-A1 | Process for preparation of benzylpiperidine compounds | MIKI SHOKYO | 2006-05-04 | — | — | US | disclosed |
| US-20050038257-A1 | Process for preparation of benzylpiperidine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-17 | — | — | US | disclosed |
| US-6833457-B1 | Process for preparation of benzylpiperidine compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-21 | — | — | US | disclosed |
| EP-1359145-A1 | PROCESS FOR PREPARATION OF BENZYLPIPERIDINE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2003-11-05 | — | — | EP | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255345-A1 | IRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | CCR5, CXCR3, CCR2 | CCR5 1/4885MEN1 3414/4885KMT2A 3682/4885 |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | CCR5 1/4885MEN1 2216/4885KMT2A 2421/4885 |
| US-20050038257-A1 | Process for preparation of benzylpiperidine compounds | SBDS, DRD4, HRH1 | CCR5 3023/4885MEN1 1277/4885KMT2A 691/4885 |
| US-20110313144-A1 | iRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | CCR5, CXCR3, CCR2 | CCR5 1/4885MEN1 3414/4885KMT2A 3682/4885 |
| US-20060094877-A1 | Process for preparation of benzylpiperidine compounds | SBDS, DRD4, HRH1 | CCR5 3023/4885MEN1 1277/4885KMT2A 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.